The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015
Corresponding Author
William J. Jagust
Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA
Corresponding author. Tel.: +1-510-643-6537.
E-mail address: [email protected]
Search for more papers by this authorSusan M. Landau
Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA
Search for more papers by this authorRobert A. Koeppe
Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, MI, USA
Search for more papers by this authorChester A. Mathis
Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA
Search for more papers by this authorJulie C. Price
Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA
Search for more papers by this authorNorman L. Foster
Department of Neurology, Center for Alzheimer's Care, Imaging and Research, University of Utah, Salt Lake City, UT, USA
Search for more papers by this authorAngela Y. Wang
Department of Neurology, Center for Alzheimer's Care, Imaging and Research, University of Utah, Salt Lake City, UT, USA
Search for more papers by this authorCorresponding Author
William J. Jagust
Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA
Corresponding author. Tel.: +1-510-643-6537.
E-mail address: [email protected]
Search for more papers by this authorSusan M. Landau
Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA
Search for more papers by this authorRobert A. Koeppe
Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, MI, USA
Search for more papers by this authorChester A. Mathis
Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA
Search for more papers by this authorJulie C. Price
Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA
Search for more papers by this authorNorman L. Foster
Department of Neurology, Center for Alzheimer's Care, Imaging and Research, University of Utah, Salt Lake City, UT, USA
Search for more papers by this authorAngela Y. Wang
Department of Neurology, Center for Alzheimer's Care, Imaging and Research, University of Utah, Salt Lake City, UT, USA
Search for more papers by this authorAbstract
Introduction
This article reviews the work done in the Alzheimer's Disease Neuroimaging Initiative positron emission tomography (ADNI PET) core over the past 5 years, largely concerning techniques, methods, and results related to amyloid imaging in ADNI.
Methods
The PET Core has used [18F]florbetapir routinely on ADNI participants, with over 1600 scans available for download. Four different laboratories are involved in data analysis, and have examined factors such as longitudinal florbetapir analysis, use of [18F]fluorodeoxyglucose (FDG)-PET in clinical trials, and relationships between different biomarkers and cognition.
Results
Converging evidence from the PET Core has indicated that cross-sectional and longitudinal florbetapir analyses require different reference regions. Studies have also examined the relationship between florbetapir data obtained immediately after injection, which reflects perfusion, and FDG-PET results. Finally, standardization has included the translation of florbetapir PET data to a centiloid scale.
Conclusion
The PET Core has demonstrated a variety of methods for the standardization of biomarkers such as florbetapir PET in a multicenter setting.
References
- 1Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010; 6: 221–229
- 2Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014; 370: 322–333
- 3Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 study: stopping AD before symptoms begin?. Sci Transl Med. 2014; 6: 228fs13
- 4Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme; 1988.
- 5Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012; 72: 578–586
- 6Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013; 12: 357–367
- 7Jack CRJr., Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, et al. Brain beta-amyloid load approaches a plateau. Neurology. 2013; 80: 890–896
- 8Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of longitudinal beta-amyloid change with 18f-florbetapir pet and standardized uptake value ratios. J Nucl Med. 2015; 56: 567–574
- 9Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid-beta PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015; 56: 560–566
- 10Brendel M, Hogenauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, et al. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage. 2015; 108: 450–459
- 11Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005; 25: 1528–1547
- 12Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MDSr., Jagust WJ, et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015; 11: 1–15.e4
- 13Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol. 2013; 74: 826–836
- 14Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease. Brain. 2015; 138: 772–783
- 15Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, et al. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014; 41: 1398–1407
- 16Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010; 68: 319–329
- 17Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O'Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2012; 39: 983–989
- 18Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, et al. Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011; 68: 1257–1266
- 19Jack CRJr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12: 207–216
- 20Jack CRJr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010; 9: 119–128
- 21Lo RY, Jagust WJ Alzheimer's Disease Neuroimaging Initiative. Vascular burden and Alzheimer disease pathologic progression. Neurology. 2012; 79: 1349–1355
- 22Haight TJ, Landau SM, Carmichael O, Schwarz C, DeCarli C, Jagust WJ, et al. Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. JAMA Neurol. 2013; 70: 1039–1045
- 23Langbaum JB, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage. 2009; 45: 1107–1116
- 24Chen K, Ayutyanont N, Langbaum JB, Fleisher AS, Reschke C, Lee W, et al. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage. 2011; 56: 52–60
- 25Chen K, Langbaum JB, Fleisher AS, Ayutyanont N, Reschke C, Lee W, et al. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative. Neuroimage. 2010; 51: 654–664
- 26Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, et al. The Alzheimer's Disease Neuroimaging Initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement. 2010; 6: 257–264
- 27Caroli A, Prestia A, Chen K, Ayutyanont N, Landau SM, Madison CM, et al. Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med. 2012; 53: 592–600
- 28Schraml F, Chen K, Ayutyanont N, Auttawut R, Langbaum JB, Lee W, et al. Association between an Alzheimer's disease-related index and gene dose. PLoS One. 2013; 8: e67163
10.1371/journal.pone.0067163 Google Scholar
- 29Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gutierrez Gomez M, Langois CM, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol. 2015; 72: 316–324
- 30Protas HD, Chen K, Langbaum JB, Fleisher AS, Alexander GE, Lee W, et al. Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol. 2013; 70: 320–325
- 31Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A, et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun. 2013; 1: 65
- 32Toledo JB, Weiner MW, Wolk DA, Da X, Chen K, Arnold SE, et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun. 2014; 2: 26
- 33Shi J, Stonnington CM, Thompson PM, Chen K, Gutman B, Reschke C, et al. Studying ventricular abnormalities in mild cognitive impairment with hyperbolic Ricci flow and tensor-based morphometry. Neuroimage. 2015; 104: 1–20
- 34Wu X, Li J, Ayutyanont N, Protas H, Jagust W, Fleisher A, et al. The receiver operational characteristic for binary classification with multiple indices and its application to the neuroimaging study of Alzheimer's disease. IEEE/ACM Trans Comput Biol Bioinform. 2013; 10: 173–180
- 35Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, et al. A multi-center randomized proof-of-concept clinical trial applying [(1)(8)F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimers Dis. 2010; 22: 1241–1256
- 36Wang T, Huang Q, Reiman EM, Chen K, Li X, Li G, et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial. J Clin Psychopharmacol. 2013; 33: 636–642
- 37Langbaum JB, Fleisher AS, Chen K, Ayutyanont N, Lopera F, Quiroz YT, et al. Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol. 2013; 9: 371–381
- 38Reiman EM, Langbaum JB, Tariot PN. Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med. 2010; 4: 3–14
- 39Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med. 1994; 35: 1528–1537
- 40Rostomian AH, Madison C, Rabinovici GD, Jagust WJ. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med. 2011; 52: 173–179
- 41Hsiao IT, Huang CC, Hsieh CJ, Hsu WC, Wey SP, Yen TC, et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging. 2012; 39: 613–620
- 42Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Mapp. 1999; 7: 254–266
- 43Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013; 54: 70–77
- 44Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013; 34: 457–468
- 45Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013; 79: 1094–1108
- 46Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014; 137: 1762–1771
- 47Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015; 14: 114–124
- 48Ossenkoppele R, Schonhaut DR, Baker SL, O'Neil JP, Janabi M, Ghosh PM, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol. 2015; 77: 338–342
- 49Jack CRJr., Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012; 71: 765–775
